Abstract
BackgroundOsteoporosis is a metabolic bone disorder characterized by a systemic impairment of bone mass and microarchitecture that results in fragility fractures [1]. Romosozumab (Rmab), a humanized monoclonal anti-sclerostin antibody, increases...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
